Adagene (ADAG) Receivables - Other (2019 - 2026)
Adagene (ADAG) posted quarterly Receivables - Other of $17.3 billion for Q4 2025, up 108.8% year-over-year from $8.3 billion in Q4 2024, and up 296057920.48% quarter-over-quarter from $5860.0 in Q2 2025.
Adagene (ADAG) Receivables - Other (2019 - 2026) Analysis & Trends
Adagene (ADAG) has reported Receivables - Other for 7 consecutive years, with $17.3 billion the latest figure, recorded in Q4 2025.
- In Q4 2025, Receivables - Other rose 108.8% year-over-year to $17.3 billion; the TTM figure through Dec 2025 stood at $17.3 billion (up 108.8% YoY), while the FY2025 annual figure was $17.3 billion, up 108.8% from the prior year.
- Receivables - Other rose to $17.3 billion in Q4 2025 per ADAG's latest filing, from $5860.0 in the prior quarter.
- Across five years, Receivables - Other topped out at $1870.1 billion in Q2 2022 and bottomed at $5860.0 in Q2 2025.
- Historically, Receivables - Other has averaged $313.1 billion across 5 years, with a median of $12.8 billion in 2024.
- Annual changes were most pronounced in 2022 — Receivables - Other jumped 201428797.64% — and 2024, when it sank 100.0%.
- Adagene's Receivables - Other stood at $4.5 million in 2021, then jumped by 13744682.73% to $619.4 billion in 2022, then sank by 64.16% to $222.0 billion in 2023, then tumbled by 96.26% to $8.3 billion in 2024, then jumped by 108.8% to $17.3 billion in 2025.
- Business Quant data shows ADAG's Receivables - Other at $17.3 billion in Q4 2025, $5860.0 in Q2 2025, and $8.3 billion in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Adagene | 310.54 Mn | 310.54 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3,025.00 |
| Jun 30, 2026 | 3,025.00 |
| Dec 31, 2025 | 17.35 Bn |
| Dec 31, 2025 | 17.35 Bn |
| Jun 30, 2025 | 5,860.00 |
| Jun 30, 2025 | 5,860.00 |
| Dec 31, 2024 | 8.31 Bn |
| Dec 31, 2024 | 8.31 Bn |
| Jun 30, 2024 | 190,608.00 |
| Jun 30, 2024 | 190,608.00 |
| Dec 31, 2023 | 222.03 Bn |
| Dec 31, 2023 | 222.03 Bn |
| Jun 30, 2023 | 393.97 Bn |
| Jun 30, 2023 | 393.97 Bn |
| Dec 31, 2022 | 619.43 Bn |
| Dec 31, 2022 | 619.43 Bn |
| Jun 30, 2022 | 1,870.08 Bn |
| Jun 30, 2022 | 1,870.08 Bn |
| Dec 31, 2021 | 4.51 Mn |
| Dec 31, 2021 | 4.51 Mn |